On July 31, 2026, Berkshire Hathaway Inc., a significant 10% owner of DaVita (DVA), reported an open-market sale of 182,980 shares at a price of $199.55, totaling $36.5 million. This transaction occurred just four days before DaVita's robust second-quarter 2026 earnings release on August 4, a quarter that saw the company exceed earnings expectations and reaffirm its full-year guidance. This timing highlights a critical distinction: Berkshire's sale appears to be a systematic, contractually driven reduction of its stake, rather than a reaction to any perceived deterioration in DaVita's operational performance.
DaVita's relationship with Berkshire is governed by a 2024 Share Repurchase Agreement. This pact mandates that if DaVita's own share buybacks cause Berkshire's ownership to exceed 45% of outstanding shares, Berkshire must sell enough stock back to DaVita on a quarterly basis to reset its stake to that 45% threshold. These sales are priced at the volume-weighted average price (VWAP) of DaVita's public repurchases. This established mechanism suggests the recent $36.5 million sale is simply another installment in a multi-year de-risking process for a large, long-held, and highly profitable position. Meanwhile, DaVita's stock currently trades at $227.99, close to its 52-week high of $244.49, implying that Berkshire is monetizing into market strength, rather than fleeing weakness.
DaVita's recent financial performance underscores robust operational execution, particularly in the latest quarter. For the second quarter of 2026, the company reported consolidated revenues of $3,554.1 million, an increase of 4.0% sequentially from the first quarter. Operating income saw an even more significant jump, rising 20.1% quarter-over-quarter to $579.0 million, pushing the operating margin to 16.3% from 14.1% in the prior quarter. This substantial operating leverage demonstrates DaVita's ability to translate revenue growth into outsized profit expansion.
Diluted earnings per share (EPS) surged 40.1% quarter-over-quarter to $4.02, while free cash flow dramatically improved by 82.9% to $256 million. For the first half of 2026, the company posted diluted EPS of $6.86, a remarkable 50.1% increase over the first half of 2025. Operating cash flow also climbed 8.5% year-over-year in the first half to $2,193 million, supporting aggressive capital allocation policies. As of June 30, 2026, DaVita's net debt to consolidated EBITDA ratio stood at approximately 3.37x, well within its covenant limit of 5.0x, providing ample financial flexibility.
| Period (Quarter End) | Revenue ($M) | Operating Income ($M) | Operating Margin | Diluted EPS ($) | Free Cash Flow ($M) |
|---|---|---|---|---|---|
| Q2 2026 (6/30/26) | 3,554.1 | 579.0 | 16.3% | 4.02 | 256 |
| Q1 2026 (3/31/26) | 3,415.5 | 481.9 | 14.1% | 2.87 | 140 |
| Q4 2025 (12/31/25) | 3,620.0 | 561.0 | 15.5% | 3.12 | 198 |
| Q3 2025 (9/30/25) | 3,420.2 | 505.8 | 14.8% | 2.04 | 604 |
This table highlights the consistent operational improvements DaVita has achieved. The company continues to invest in share repurchases, retiring 2.2 million shares for $348 million in Q2 2026 at an average price of $154.95 per share. Post-quarter, it repurchased an additional 0.2 million shares at an average of $199.55, matching the price of Berkshire's July sale. These buybacks not only return capital to shareholders but also contribute significantly to the per-share earnings growth.
The recent DaVita share sales by Berkshire Hathaway are more indicative of a systematic portfolio rebalancing and profit-taking by a sophisticated, long-term investor than a sudden loss of confidence. Berkshire first acquired a significant stake in DaVita in the fourth quarter of 2011 at an average price around $49.41. This original investment of approximately $1.54 billion has since generated substantial unrealized gains, reportedly in the range of 334% to 349% before accounting for any dividends or buyback-driven share count reductions.
Berkshire's management, including Warren Buffett, has explicitly stated its philosophy regarding investment gains and losses: "We believe that investment gains and losses, whether realized from dispositions or unrealized from changes in market prices, are generally meaningless in understanding our reported periodic results or evaluating our periodic economic performance." The 2024 Share Repurchase Agreement with DaVita further formalizes a mechanism for Berkshire to trim its position. This agreement mandates that if DaVita's ongoing share repurchases cause Berkshire's ownership to exceed 45%, Berkshire must sell shares back to DaVita at the volume-weighted average price of DaVita's repurchases from other public shareholders. This covenant dictates a programmatic, mechanical reduction, insulating these sales from being interpreted as a discretionary "vote" on DaVita's fundamentals.
This programmatic trimming aligns with Berkshire's broader portfolio adjustments. In the first quarter of 2026, Berkshire reported $8.15 billion in net equity sales, including full exits from its substantial UnitedHealth Group ($1.4 billion), Visa (around $2.91 billion), and Mastercard (around $2.28 billion) stakes. Against this backdrop, the $36.5 million DaVita sale on July 31 is economically trivial, representing roughly 0.45% of Berkshire's net equity sales for the first quarter of 2026, and a mere 0.8% of its DaVita position. Other senior executives at DaVita also engaged in selling activity in the second quarter of 2026. CEO Javier Rodriguez sold 69,407 shares for $14.53 million in mid-June at an average price of approximately $209.38, while Chief Legal and Public Affairs Officer Kathleen Alyce Waters sold 15,405 shares for $3.21 million around the same time at an average price near $208.50. These sales, occurring at prices above $200 per share and just weeks before strong Q2 results, are consistent with personal diversification and profit-taking in a highly appreciated stock rather than a reaction to deteriorating business conditions.
Despite strong operational performance and a seemingly benign explanation for insider sales, DaVita navigates a complex and intensifying regulatory landscape that poses structural risks to its long-term growth and profitability. The Federal Trade Commission (FTC) initiated investigations in April 2024, issuing Civil Investigative Demands concerning DaVita’s acquisition of medical director services, the provision of dialysis services, and, notably, the use of restrictive covenants and non-compete clauses with nephrologists. These probes extend to scrutinizing whether DaVita and its main competitor, Fresenius, "illegally thwart smaller competitors" and potentially limit patient access to critical innovations like home dialysis. Such actions, if deemed unlawful, could restrict DaVita's ability to consolidate the market, secure physician referrals, and deploy new care models.
DaVita's business model is also heavily exposed to Medicare reimbursement policies. With 57% of its U.S. dialysis patient service revenue derived from Medicare and Medicare Advantage programs, changes to the End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) can significantly impact financials. While the Calendar Year (CY) 2026 ESRD PPS Final Rule set a base rate increase of approximately 2.9%, the proposed CY 2027 rule, with its inclusion of phosphate binders into the dialysis bundle, suggests that effective reimbursement per treatment might lag underlying cost inflation. DaVita's management commentary highlights that such changes, even if seemingly minor, can create earnings volatility by impacting revenue per treatment and increasing costs. Even a 1-2% unfavorable adjustment to ESRD PPS rates could translate into $100-200 million swings in annual operating income on a guided base of $2.15-2.25 billion for 2026.
Beyond direct reimbursement, DaVita faces ongoing investigations by the District of Columbia Attorney General regarding antitrust issues related to the American Kidney Fund, and separate probes by the U.S. Attorney in New Jersey and the California Department of Insurance concerning joint ventures and insurance practices. While legal accruals currently remain "immaterial," DaVita's 2025 10-K explicitly warns that actual losses from these matters "could differ materially" from estimates. These multi-front regulatory and legal pressures create an inherent, persistent risk premium on DaVita's shares, acting as a rational, if unspoken, impetus for a long-term, concentrated investor like Berkshire to manage its exposure, even in the face of strong operating results.
DaVita's current market valuation presents a nuanced picture, reflecting both its operational strength and the underlying risks. As of August 4, 2026, DaVita shares trade at $227.99, giving it a market capitalization of $14.63 billion. The company's trailing twelve-month (TTM) price-to-earnings (P/E) ratio stands at approximately 22.27x to 22.68x. While this valuation might seem reasonable in isolation, it represents a substantial 40% premium over DaVita's own 10-year median P/E of 15.88x. This suggests that the market is already pricing in a significant portion of the company's recent operational outperformance and strong guidance.
When compared to its closest peer, Fresenius Medical Care (FMS), DaVita's premium becomes even more evident. Fresenius trades at a TTM P/E of around 13.69x, implying that DaVita carries a 62.7% P/E premium over its direct competitor. Similarly, DaVita's EV/EBITDA multiple of 9.16x is 46.6% higher than Fresenius's 6.25x. While some of this premium can be justified by DaVita's superior operating margins (16.3% in Q2 2026 versus Fresenius's 9.6%) and faster EPS growth trajectory, it signals high market expectations. If DaVita's P/E multiple were to revert to its 10-year median of 15.88x, holding TTM EPS constant, the implied share price would be approximately $171.40, representing a substantial 28.7% downside from current levels.
Conversely, DaVita's forward P/E, based on the midpoint of its 2026 adjusted EPS guidance of $14.65, computes to approximately 15.6x. This forward multiple is more in line with its historical averages and even offers a discount to the broader market's forward P/E, which is around 26.31x. This dichotomy suggests that while the market acknowledges DaVita's strong near-term earnings power, it simultaneously discounts potential future headwinds or a re-rating of the stock to its historical valuation bands. The current valuation effectively demands flawless execution and a benign regulatory environment, leaving little margin for error.
Wall Street's collective sentiment on DaVita reflects a nuanced perspective, balancing the company's solid operational performance against its valuation and the inherent risks of a highly regulated industry. The consensus rating among 23 analysts is "Hold," with a distribution of 9 "Buy" ratings, 13 "Hold" ratings, and 1 "Sell" rating. This balanced outlook suggests that while analysts recognize DaVita's strengths, they are not overwhelmingly bullish on the stock's near-term upside from current levels.
Analyst price targets for DaVita exhibit a moderate spread. The consensus 12-month target stands at $239.50, with a median target of $235.00. The high target reaches $270.00, while the low target is $218.00. Against the current price of $227.99, these targets imply a modest upside: approximately 5.1% to the consensus target and 3.1% to the median. The most optimistic high target suggests an 18.4% upside, while the low target implies a 4.4% downside.
| Firm | Analyst | Rating | Price Target | Date |
|---|---|---|---|---|
| UBS | A.J. Rice | Buy | $270.00 | 2026-07-10 |
| Truist Securities | David Macdonald | Hold | $250.00 | 2026-07-14 |
| Barclays | Andrew Mok | Equal-Weight | $218.00 | 2026-07-09 |
| TD Cowen | Ryan Langston | Hold | $201.00 | 2026-05-11 |
| BofA Securities | Kevin Fischbeck | Underperform | $145.00 | 2025-09-10 |
This table illustrates the range of views among covering analysts. Notably, the most recent price target updates from Truist Securities and UBS came with "Hold" and "Buy" ratings respectively, but even with increased targets, they suggest limited upside from current trading levels. The presence of an "Underperform" rating from BofA Securities with a significantly lower target of $145.00 underscores the potential for a more bearish interpretation, particularly if the valuation premium becomes unsustainable or regulatory risks crystallize.
The most compelling argument for DaVita's continued strength, which challenges a cautious outlook, lies in its consistently robust financial performance and management's effective execution. The second quarter of 2026 showcased impressive results: diluted EPS of $4.02, beating expectations, and consolidated revenues of $3.554 billion. Critically, operating income soared 20.1% sequentially, pushing the operating margin to a healthy 16.3% from 14.1% in the prior quarter. For the first half of 2026, DaVita delivered a remarkable 50.1% year-over-year growth in EPS and a 12.6% increase in free cash flow, reaffirming its full-year guidance for adjusted operating income of $2.15-2.25 billion and adjusted EPS of $14.10-15.20. As CEO Javier Rodriguez noted, "Thanks to the outstanding efforts of our teammates, we had another positive quarter for both patient outcomes and financial results." This sustained operational momentum and clear earnings growth trajectory are powerful indicators that DaVita is executing well within its challenging environment, suggesting the stock should indeed command a premium.
However, even this strong fundamental picture must be viewed through the lens of a highly appreciated valuation and persistent, policy-driven risks. While the 70% sequential incremental operating margin observed between Q1 and Q2 2026 is exceptional, such high levels of operating leverage are unlikely to be sustained indefinitely. The market, by pricing DaVita at a 40% premium to its 10-year median P/E, has already incorporated much of this impressive execution. Berkshire Hathaway's and other insiders' sales, though mechanistic and for personal diversification, underscore a rational long-term assessment of the risk-reward balance. For a sophisticated investor, even stellar earnings can be overshadowed by the potential for multiple compression due to unquantifiable regulatory and reimbursement risks, such as the persistent FTC antitrust probes or the lag in Medicare payment updates against rising costs. The "measured de-risking" by Berkshire, a long-term holder, suggests that while DaVita's business is fundamentally strong, the external environment places an inherent cap on its long-term return potential. The thesis of caution would be definitively challenged if DaVita could sustain high-teens EPS growth without any multiple compression, pushing its valuation significantly higher, or if a material relaxation in regulatory pressures were to occur.
DaVita (DVA) stands at a crossroads where robust operational performance meets a landscape of persistent regulatory scrutiny and a premium valuation. While the company's strong Q2 2026 results, impressive earnings per share growth, and consistent cash flow generation paint a picture of fundamental health, the market has already largely priced in this success. Berkshire Hathaway's ongoing, programmatic sales, alongside other insider divestitures, reflect a rational strategy of profit-taking and portfolio re-balancing in a highly appreciated asset, rather than a bearish signal on DaVita's core business. However, these sales also highlight the company's inherent exposure to policy shifts and antitrust challenges that loom large over its concentrated market share.
For investors, the current risk-reward profile of DaVita appears balanced, but with a tilt toward caution. The stock's current price of $227.99 is near its 52-week high and trades at a significant premium to its historical valuation and peers like Fresenius Medical Care. While the near-term earnings trajectory is compelling, the potential for multiple compression due to regulatory headwinds, such as the ongoing FTC investigations into non-competes and the ever-present threat of unfavorable Medicare reimbursement changes, cannot be ignored. Wall Street's "Hold" consensus and modest price targets further reinforce this tempered outlook.
Our verdict is Neutral. We believe DaVita's operational strength is commendable, but the valuation already discounts much of this, and the persistent regulatory overhang limits significant upside. An entry zone for new positions would ideally be closer to the prior insider selling levels, perhaps around $200-$210, which aligns with both Berkshire's recent sale price and DaVita's own post-Q2 buybacks, offering a better risk-adjusted entry point. Our 12-month price target is $235, aligning with the median analyst target, reflecting the company's solid fundamentals but acknowledging the valuation ceiling imposed by industry-specific risks. This target implies modest upside from current levels. The invalidation level for this neutral stance would be a sustained break below $180, which would indicate a meaningful deterioration in either fundamental performance or an acceleration of multiple compression due to policy setbacks or unexpected legal costs.
Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.
